Keyphrases
Temsirolimus
100%
Erlotinib
100%
Phase I Trial
100%
Refractory Solid Tumors
100%
Expansion Cohort
57%
Recommended Phase 2 Dose
57%
Dose Escalation
28%
Diarrhea
14%
Phosphoinositide 3-kinase (PI3K)
14%
Nausea
14%
Mammalian Target of Rapamycin (mTOR)
14%
Epidermal Growth Factor Receptor
14%
Dose-limiting Toxicity
14%
Phase I Study
14%
Renal Failure
14%
Complete Response
14%
Partial Response
14%
Starting Dose
14%
Dose Level
14%
Patient Selection
14%
Epidermal Growth Factor Receptor Signaling
14%
Stable Disease
14%
Progressive Disease
14%
Rash
14%
MTOR Inhibitor
14%
Drug Adverse Events
14%
Squamous Histology
14%
Pathway Activation
14%
Epidermal Growth Factor Receptor Inhibitors
14%
Resistance to Treatment
14%
Dehydration
14%
Mucositis
14%
Disease Stabilization
14%
Stomatitis
14%
3 + 3 Design
14%
25Mg
14%
Pharmacology, Toxicology and Pharmaceutical Science
Solid Malignant Neoplasm
100%
Temsirolimus
100%
Erlotinib
100%
Phase I Trials
100%
Disease
42%
Epidermal Growth Factor Receptor
28%
Diarrhea
14%
Nausea
14%
Adverse Event
14%
Kidney Failure
14%
Rash
14%
Mammalian Target of Rapamycin
14%
Mammalian Target of Rapamycin Inhibitor
14%
Epidermal Growth Factor Receptor Kinase Inhibitor
14%
Mucosa Inflammation
14%
Stomatitis
14%